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We conducted a retrospective multicenter study including pediatric and adult patients
with acute leukemia (AL) who received donor lymphocyte infusions (DLIs) after allogeneic
hematopoietic stem cell transplantation (HCT) between January 1, 2010 and December
31, 2015, in order to determine the efficacy and toxicity of the immune treatment. Two
hundred fifty-two patients, median age 45.1 years (1.6–73.4), were enrolled from 34
Italian transplant centers. The underlying disease was acute myeloid leukemia in 180
cases (71%). Donors were HLA identical or 1 locus mismatched sibling (40%), unrelated
(40%), or haploidentical (20%). The first DLI was administered at a median time of 258
days (55–3,784) after HCT. The main indication for DLI was leukemia relapse (73%),
followed by mixed chimerism (17%), and pre-emptive/prophylactic use (10%). Ninety-
six patients (38%) received one single infusion, whereas 65 (26%), 42 (17%), and 49
patients (19%) received 2, 3, or ≥4 infusions, respectively, with a median of 31 days
between two subsequent DLIs. Forty percent of evaluable patients received no treatment
before the first DLI, whereas radiotherapy, conventional chemotherapy or targeted
treatments were administered in 3, 39, and 18%, respectively. In informative patients, a
few severe adverse events were reported: grade III–IV graft versus host disease (GVHD)
(3%), grade III–IV hematological toxicity (11%), and DLI-related mortality (9%). Forty-six
patients (18%) received a second HCT after a median of 232 days (32–1,390) from
the first DLI. With a median follow-up of 461 days (2–3,255) after the first DLI, 1-, 3-,
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and 5- year overall survival (OS) of the whole group from start of DLI treatment was 55,
39, and 33%, respectively. In multivariate analysis, older recipient age, and transplants
from haploidentical donors significantly reduced OS, whereas DLI for mixed chimerism or
as pre-emptive/prophylactic treatment compared to DLI for AL relapse and a schedule
including more than one DLI significantly prolonged OS. This GITMO survey confirms that
DLI administration in absence of overt hematological relapse and multiple infusions are
associated with a favorable outcome in AL patients. DLI from haploidentical donors had
a poor outcome and may represent an area of further investigation.
Keywords: donor lymphocyte infusions, relapse, allogeneic stem cell transplantation, acute leukemia, pre-emptive
treatment
INTRODUCTION
Disease relapse is the leading cause of treatment failure and
mortality in patients with acute leukemia (AL) undergoing
allogeneic hematopoietic stem cell transplantation (HCT). Most
relapses occur within 1 year after HCT and exhibit a progressive
clinical course. Two main mechanisms may be responsible
for relapse after HCT: tumor cells may escape from the
impact of pre-transplant conditioning chemotherapy regimens
or tumor cells may evade post-transplant immune control. Many
treatment strategies, including pharmaceutical and cell-based
treatments, have been developed and tested to prevent and treat
relapses. Donor lymphocyte infusion (DLI) is a form of adoptive
immunotherapy aiming to enhance the graft-versus-leukemia
(GVL) effect after HCT. DLIs were first used in patients suffering
from chronic myeloid leukemia (CML) relapse after HCT. In
these patients, especially in the case of cytogenetic or molecular
relapse, DLIs achieved a high rate of complete responses (up to
80%) compared to patients with other hematological disorders
(1–3). In patients with acute leukemia, clinical responses have
been reported to be fewer, particularly in the case of overt relapse
and in the presence of acute lymphoid leukemia (4–8). Moreover,
clinical success is limited by the occurrence of acute and
chronic graft-versus-host disease (GVHD), marrow aplasia and
infections, which can be all causes of treatment-related mortality
in up to 20% of patients (9, 10). To determine the efficacy and
toxicity of DLIs and to identify potential factors influencing
the outcome, we conducted a retrospective multicenter study
including patients with AL who received DLIs after HCT from
related and unrelated donors.
METHODS
Study Design and Information Collection
This was a multicenter retrospective study carried out in Italian
transplant centers coordinated by the Gruppo Italiano per il
Trapianto Midollo Osseo e Terapia Cellulare (GITMO) network.
Criteria for patient eligibility were the following: adult and
pediatric patients, without age limit; diagnosis of acute myeloid
leukemia (AML) or acute lymphoblastic leukemia (ALL); any
stage of disease at transplant; first HCT from HLA-identical
sibling or volunteer or mismatched related donor; myeloablative
or reduced-intensity conditioning (RIC) regimen; and at least 1
unmanipulated DLI administered between January 1, 2010 and
December 31, 2015. Exclusion criteria included: DLI treatment
after second or further HCT, T-cell depleted transplant,
and diagnosis other than AL. The primary endpoint was overall
survival (OS). The secondary endpoints were: indications for DLI
administration and the DLI schedule most commonly adopted
among the GITMO centers, response rate, non-relapse mortality
(NRM), hematological toxicity, and acute and chronic GVHD
incidence. Thirty-four GITMO centers accredited for allogeneic
HCT participated in the study. Information was collected
in two phases. In the first phase, a survey was conducted to
collect the data of the 34 participating centers from the GITMO
registry. The data collected were the following: demographic
data, relationship and HLA compatibility of patients and donors,
AL type, conditioning, stem cell source, GVHD prophylaxis,
acute and chronic GVHD after transplantation, relapse, patient
and disease status at last follow-up, date of DLI administration,
clinical indication for DLI administration, possible treatments
administered before DLI, and date of possible second HCT.
In the second phase, the participating centers were asked to
provide data that were missing from the GITMO registry.
The data provided were the following: cell doses, transfusion
schedule, hematological and non-hematological toxicity,
acute and chronic GVHD after DLIs, and disease response.
Fifteen centers agreed to and completed the second part of
the study.
Ethics Section
The study involving human participants was reviewed and
approved by the Ethics Committee of the center of the national
principal investigator, called “Comitato Unico Regionale Friuli-
Venezia-Giulia” on 2017, 3 October (Protocol Number 26522)
and by the Ethics Committees of all participating institutions.
A written and informed consent was obtained from all patients
according to the Declaration of Helsinki.
Definitions
DLI was defined as transfusion of unstimulated lymphocyte
concentrates, collected from the original stem cell donor as buffy
coat preparations, or as transfusion of unmanipulated mobilized
peripheral blood stem cells (PBSC). RIC regimens were defined
as described by Bacigalupo et al. (11). Acute GVHD was graded
according to the 1994 Consensus Conference on acute GVHD
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TABLE 1 | Characteristics of patients and allogeneic transplants.
Total number of patients 252
Sex: male 133 (53%)
Median age (range) at transplant 45.1 (1.6–73.4)
Age <18 years 13 (5%)
Diagnosis
AML [secondary AML] 180 (71%) [32 (17%)]
ALL [Ph+ ALL] 68 (27%) [8 (12%)]





Disease status at transplant
Not treated 2 (1%)
1 CR 135 (54%)
≥2 CR 61 (25%)




HLA-matched sibling 98 (39%)




Bone marrow 83 (33%)
Peripheral blood 169 (67%)
Conditioning regimen
Myeloablative (with TBI) 42 (17%)
Myeloablative (only drugs) 137 (55%)
Reduced intensity 71 (28%)
GVHD prophylaxis
CyA/FK + MTX 80 (32%)





Grade 0 169 (68%)
Grade I 42 (17%)
Grade II 27 (11%)







No, number; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; Ph+,
Philadelphia chromosome positive; CR, complete remission; TBI, total body irradiation;
CyA, cyclosporine; FK, tacrolimus; MTX, methotrexate; ATG, antithymocyte globulin;
PT-Cy, post-transplant cyclophosphamide.
grading criteria (12), and chronic GVHD was staged according
to the criteria developed by the National Institute of Health
(13). Hematological relapse was defined by recurrence of blasts
in PB or infiltration of bone marrow (BM) by more than 5%
blasts. Pre-emptive treatment was defined as DLI administration
in cases of reappearance of minimal residual disease (MRD)
(any AL cytogenetic or molecular or phenotypic marker
previously detected at diagnosis) in absence of hematological
relapse. Prophylaxis was defined as DLI treatment to prevent
hematological relapse in patients with negative MRD. Mixed
chimerism was defined as failure to achieve >95% of donor cells
or decreased chimerism, with evidence of AL complete remission.
Targeted therapy before DLI included hypomethylating agents
in patients with AML and tyrosine kinase inhibitors in patients
with ALL.
Statistical Analysis
Data were collected in an XLS database and imported into
Stata/SE 9.0 for Windows (StataCorp, College Station, TX)
for statistical analysis. The close-out date for analysis was
December 2018. The starting points of our analyses were day
of first HCT and day of first DLI. NRM was defined as death
due to all causes not related to leukemia and was estimated
with the cumulative incidence method. OS was defined as
the time (days) from the aforementioned starting points to
either death or last observation and was described using the
Kaplan-Meier approach.
In univariate analysis, variables considered as possible
prognostic factors were: age at transplantation (years), sex,
AL type (AML or ALL), conditioning intensity (myeloablative
or RIC), GVHD prophylaxis (calcineurin inhibitors plus
methotrexate or calcineurin inhibitors plus methotrexate plus
antithymocyte serum or post-transplant cyclophosphamide or
other platforms), donor type (HLA-identical plus 1 antigen
mismatched related donor vs. unrelated donor vs. haploidentical
donor), time between HCT and first DLI (≤180 days, 181–
365 days, 366–730 days, >730 days), indication for DLI
administration (relapse or mixed chimerism or pre-emptive
treatment/prophylaxis), treatment administered before DLI (no
pharmacological treatment or conventional chemotherapy or
targeted therapy), number of infusions, and acute or chronic
GVHD after HCT (yes or no). Acute and chronic GVHD
were treated as time-dependent variables. Multivariate stepwise
analyses included all variables found to be significant at p ≤ 0.10
on univariate analysis. Retention in the stepwise model required
the variable to be significant at p ≤ 0.05.
RESULTS
Patient and Transplant Information
(Table 1)
Two hundred fifty-two patients were enrolled from 34 Italian
transplant centers. Thirty centers (86%) provided data for <10
patients. One hundred thirty-three patients (53%) were male and
median age at transplant was 45.1 years (range 1.6–73.4). Only
13 patients (5%) were younger than 18 years. The underlying
disease was AML in 180 patients (71%), ALL in 68 patients (27%),
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TABLE 2 | Characteristics of DLIs.
1stDLI 2ndDLI 3rdDLI 4thDLI ≥5thDLI
Total number of cases 252 156 91 49 53
Time between transplant and first DLI (days) 258 (55–3,784)
Time between DLIs 29 (1-1015) 30 (2-636) 33 (7-623) 31 (13-441)
DLI indication
AL relapse 172/235 (73%) – – – –




No treatment 41/103 (40%) 110/126 (87%) 70/78 (90%) 40/47 (85%) 28/46 (61%)
Radiotherapy 3/103 (3%) – 1/78 (1%) – 1/46 (2%)
Chemotherapy 40/103 (39%) 5/126 (4%) 2/78 (2%) 2/47 (5%) –
Targeted therapy 19/103 (18%) 11/126 (9%) 6/78 (7%) 7/47 (15%) 17/46 (37%)
Missing 149 30 13 2 7
Dose (× 106/kg)
Median (range) 1 (0.01–10) 2 (0.01–64) 5 (0.05–100) 10 (0.05–50) 10 (0.05–50)
Missing 198 126 70 33 38
Acute GVHD
Grade 0 141/163 (87%) 94/106 (89%) 64/69 (93%) 36/39 (82%) 43/48 (90%)
Grade I–II 17/163 (10%) 9/106 (8%) 3/69 (4%) 2/39 (5%) 4/48 (8%)
Grade III–IV 5/163 (3%) 3/106 (3%) 2/69 (3%) 1/39 (3%) 1/48 (2%)
Missing 89 50 22 10
Grade IV hematological toxicity
Number of cases 9/82 (11%) 4/35 (11%) 4/26 (15%) 2/18 (11%) –
Missing 170 121 65 31 53
AL, acute leukemia.
and biphenotypic AL in 4 patients (2%). The majority of HCTs
(180, 71%) were performed between 2011 and 2015, whereas
the other procedures were done before 2011. Twenty percent
of patients had active AL at transplant. Preparative regimens
before HCT were myeloablative in 179 transplants (72%). One
hundred fifty patients (60%) had a related donor, who was HLA-
identical sibling, 1 locus HLA mismatched, or haploidentical
in 98, 3, and 49 cases, respectively; 102 patients (40%) had
an unrelated donor. An high resolution DNA typing was
performed at HLA-A, -B, -C, -DRB1 loci; 65 out of 91 evalutable
unrelated transplants (71%) were HLA-matched, while a single
mismatch at HLA-A, -B, or -C locus was present in 10 (11%),
6 (7%), and 10 recipient and donor pairs (11%), respectively.
One hundred sixty-nine patients (67%) received PBSC, and 83
(33%) received BM. GVHD prophylaxis consisted of calcineurin
inhibitor (cyclosporine or tacrolimus) plus methotrexate in 80
patients (32%), calcineurin inhibitor plus methotrexate plus
antithymocyte globulin (ATG) in 120 patients (48%), post-
transplant cyclophosphamide-based prophylaxis in 13 patients
(5%), and other platforms in the remaining 39 patients (15%).
Most common miscellaneous GVHD prophylaxis regimens were
used in haploidentical transplants and included rapamycin-based
and ATG plus basiliximab-based platforms. Sixty-nine of the
evaluable patients (32%) developed grade I-IV acute GVHD,
which reached grade III–IV only in 10 cases (4%). Chronic
GVHD occurred in 98 of evaluable patients (47%) and was severe
in 26 cases (12%).
DLI Administration (Table 2)
All patients received at least one DLI. The first DLI was
administered at a median time of 258 days (55–3,784) after
HCT. The main indication for DLI was leukemia relapse after
HCT (172 patients, 73%), followed by mixed chimerism (39
patients, 17%) and pre-emptive/prophylactic use (24 patients,
10%). Ninety-six patients out of 252 (38%) received one single
infusion, whereas 65 (26%), 42 (17%), and 49 patients (19%)
received 2, 3, or ≥4 infusions, respectively, with a median of 31
days between two subsequent DLIs. Forty percent of evaluable
patients received no treatment before the first DLI, whereas
radiotherapy, conventional chemotherapy or targeted treatments
were administered in 3, 39, and 18%, respectively. The percentage
of patients who did not receive any treatment in association
with DLIs increased to 87 and 90% after the second and third
DLI, respectively. The median dose of the first DLI was 1 ×
106/kg (0.01–10) for the informative patients. In case of multiple
infusions, an escalating schedule wasmainly chosen, withmedian
doses ranging from 1× 106/kg CD3+ lymphocytes (0.01–10) for
the first infusion to 10× 106/kg CD3+ lymphocytes (0.05–50) for
the fifth or further infusion. Median and range of CD3+ cells/kg
of the first DLI were 1 × 106 (0.5–10), 1 × 106 (0.1–10), and 0.3
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× 106 (0.05–1) in recipients of DLIs from HLA identical sibling,
unrelated and haploidentical donors, respectively. A sequential
schedule was administered to 36/98 (37%) recipients of DLIs
from HLA identical sibling donors, 32/102 (31%) recipients of
DLIs from unrelated donors and to 25/52 (48%) recipients of
DLIs from haploidentical donors, respectively (p = 0.127) After
the first DLI, acute GVHD was reported in 13% of informative
patients and was grade III-IV in 3% of patients. The percentage
of patients who developed acute GVHD decreased to 11 and
7% after the second and third DLI, respectively. In contrast,
the percentage of evaluable patients who developed chronic
moderate-severe GVHD requiring treatment increased from 2%
after the first DLI to 7 and 14% after the second and third DLI,
respectively. Grade III-IV neutropenia and/or thrombocytopenia
occurred in 11% of the evaluable patients after the first DLI
and the rate was not significantly different after subsequent
infusions. Severe infections were reported in 6 out 98 informative
DLIs (6%) and included invasive mycoses (2 patients), viral
infections (2 cases), and recurrent bacterial enteritis (2 patients).
Forty-five patients who received DLI because of relapse were
evaluable for response after cell infusion: 14 patients (31%)
reached complete remission, 16 patients (35%) had stable
disease, and 15 (33%) experienced leukemia progression. Forty-
six patients (18%) received a second HCT after a median of
922 days (149–1,970) from the first HCT and after a median
of 232 days (32–1,390) from the first DLI. There was no
significant difference in the proportion of patients undergoing
second HCT after receiving DLI according to immunotherapy
indication. In fact, 35 out of 172 patients (20%) who received
DLI because of relapse required a second transplant compared
to 3 out of 39 (8%) and 3 out of 24 (12%) of those who were
treated with DLI because of mixed chimerism or as prevention,
respectively (p= 0.136).
Outcome
With a median follow-up of 878 days (55–6,754) after the first
HCT and 461 days (2–3,255) after the first DLI, 81 of the 248
evaluable patients (33%) were alive and 167 (67%) were dead.
Of these latter, 141 (84%) died because of leukemia progression
and 26 (16%) because of NRM. Causes of NRM were related to
DLI (15 patients, 9%), second HCT (6 patients, 4%), secondary
malignancy (2 cases, 1%), and to other causes (3 patients, 2%).
NRM events were equally distributed between patients treated
in small centers (providing data of ≤10 patients) and large
centers (providing data of more than 10 patients): in fact, 12
out of 127 patients (9%) from small centers and 14 out of 121
patients (11%) from large centers died because of NRM (p =
0.736). Median survival was 915 days (55–6,754) from the first
HCT and 466 days (2–3,255) from the first DLI, respectively.
One-, three-, and five-year OS of the whole group from the
beginning of DLI treatment was 55, 39, and 33%, respectively
(Figure 1). Prognostic factors that were significantly (p < 0.10)
associated with OS after DLI in the univariate proportional
hazards model were: age, donor type, treatment before DLI,
indication for DLI, number of DLI, time between transplant
and first DLI (Table 3). In multivariate analysis, older recipient
age and transplants from haploidentical donors significantly
FIGURE 1 | Overall survival of the 252 patients treated with DLIs.
reduced OS (HR 1.020; 95% CI 1.008–1.033; p = 0.001 and HR
2.815; 95% CI 1.702–4.656; p= 0.000, respectively), whereas DLI
for mixed chimerism or as pre-emptive/prophylactic treatment
compared to AL relapse and a schedule including more than
one DLI significantly prolonged OS (HR 0.379; 95% CI 0.219–
0.646; p = 0.000; HR 0.202; 95% CI 0.098–0.415; p = 0.000; HR
0.876; 95% CI 0.767–1.000; p = 0.050, respectively). Moreover,
a time between transplant and first DLI longer than 2 years
significantly improved OS (HR 0.411; 95% CI 0.229–0.740; p =
0.003; Table 4). Patients who received DLI because of relapse
reported a 3-year OS of 32%, which was significantly lower
than the 3-year OS of 55 and 58% for those patients who were
treated with DLI because of mixed chimerism (p = 0.002) or
pre-emptive/prophylactic use (p = 0.008; Figure 2). Moreover,
transplants from haploidentical donors showed a 3-year OS
of 25%, which was significantly lower than that reported in
transplants from unrelated donors (3-year OS 48%, p = 0.000;
Figure 3). In addition, patients who received a second HCT after
receiving DLI showed a trend of longer OS compared to patients
who received only one transplant followed by DLI (p = 0.077;
Figure 4).
Since DLIs from haploidentical donor were an independent
predictor for worse OS, we compared toxicity and efficacy
of DLIs among matched related, unrelated and haploidentical
donors. There was no significant difference in the distribution
of NRM events among the 3 groups (p = 0.313), while acute
GVHDwas significantly more frequent after DLIs from unrelated
donors (21%) and haploidentical donors (28%) in comparison
with DLIs from HLA-identical sibling donors (7%) (unrelated
DLIs vs. HLA-identical sibling DLIs: p = 0.041; haploidentical
DLIs vs. HLA-identical sibling DLIs: p = 0.020). Moreover,
taking in account the 45 patients who received DLIs because of
leukemia relapse and were evaluable for response, we observed
a significant lower rate of leukemia control (complete remission
and stable disease) after DLIs from haploidentical donors (33%)
in comparison with DLIs from unrelated donors (78%) (p =
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TABLE 3 | Univariate analysis of overall survival data from first DLI.
Factor HR 95%CI p
Age
Modeled as continuous variable 1.012 1.001–1.024 0.027
Sex
Male 1 0.683–1.403 0.623
Female 1.084
Diagnosis




HLA-identical sibling or 1 locus
mismatched related
1.494 1.031–2.165 0.034
Haploidentical 1.843 1.199-2.883 0.005
Treatment before DLI
No treatment/RT 1
Chemotherapy 1.820 1.009–3.282 0.046
Targeted therapy 1.281 0.599–2.738 0.522
DLI indication
AL Relapse 1
Mixed chimerism 0.434 0.257–0.735 0.002
Pre-emptive/prophylaxis 0.431 0.231–0.801 0.008
Number of DLIs
Modeled as continuous variable 0.883 0.782–0.997 0.045
Time HCT-first DLI
≤180 days 1
181–356 days 0.765 0.508–1.151 0.199
366–730 days 0.915 0.599–1.395 0.680
>730 days 0.556 0.324–0.955 0.034
Number of transplants
1 1
2 0.682 0.446–1.042 0.077
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; HLA-id, HLA-identical;
MM, mismatched; RT, radiotherapy.
0.036), while no significant difference in efficacy was reported if
DLIs frommatched related donors and those from haploidentical
donors were compared (p= 0.282).
DISCUSSION
The first aim of the present survey was to take a picture of
the DLI strategy in AL patients in Italian transplant centers.
We found that DLIs were administered in 73% of patients
after AL clinical recurrence, whereas they represented a way
of preventing hematological relapse for less than one third
of cases, who received them because of mixed chimerism or
MRD positivity. The median time of about 8 months between
HCT and first DLI confirmed that immunotherapy was used
late in the course of the disease. A few EBMT registry studies
have established the efficacy of DLIs either in the setting of
overt relapse or used prophylactically. In AML relapse after
TABLE 4 | Multivariate analysis of overall survival data from first DLI.
Factor HR 95%CI p
Age
Modeled as continuous variable 1.020 1.008–1.033 0.001
Donor
Unrelated 1
HLA-identical sibling or 1 locus mismatched 1.261 0.854–1.861 0.243
Haploidentical 2.815 1.702–4.656 0.000
DLI indication
AL relapse 1
Mixed chimerism 0.379 0.219–0.646 0.000
Pre-emptive/prophylaxis 0.202 0.098–0.415 0.000
Time HCT-first DLI
≤180 days 1
181–356 days 0.741 0.468–1.172 0.201
366–730 days 0.728 0.462–1.147 0.171
>730 days 0.411 0.229–0.740 0.003
Number of DLI
Modeled as continuous variable 0.876 0.767–1.000 0.050
HLA-id, HLA-identical; MM, mismatched.
first HCT, DLIs prolonged OS in comparison with no DLIs
(14). Comparison of DLIs and second HCT showed that the
clinical benefit of DLIs was comparable to that of salvage HCT
(15). Moreover, in a matched-pair analysis, prophylactic DLIs
significantly improved outcome in high-risk AML, but failed
to achieve an OS advantage in ALL and in standard risk AML
(16). In our study, several reasons for reluctance to administer
DLI earlier after HCT may be hypothesized. First, physicians
may have feared life-threatening complications of DLIs such as
GVHD and severe infections. Indeed, in our study, toxicity after
DLI was quite low, with fatal adverse events reported in 9% of
patients, confirming the NRM incidence reported in previous
studies. Moreover, the incidence of severe acute and chronic
GVHD was lower than that reported in other registry studies
(17), although our analysis may have been limited by the small
number of informative patients. Second, a prevention strategy
needs standardized markers of MRD and regular monitoring
after CT, which might not be available in all Italian centers.
Third, contacting and preparing donors can be time-consuming,
particularly if they are volunteer donors and lymphocyte
donation has to be authorized by a GITMO committee, which
is in charge of reviewing clinical HCT history and indication
for DLI. Cryopreservation of unmanipulated mobilized PBSC
instead of leukapheresis products can enhance DLI availability
and accelerate infusions; however, data of the GITMO registry
did not allow identification of the two different products.
As expected, we reported a significant OS benefit for patients
receiving DLI because of mixed chimerism or MRD positivity in
comparison with patients receiving DLI because of hematological
relapse. These outcomes are in line with those reported by the
EBMT and the Japanese registry studies (14, 15, 18). Moreover,
multivariate analysis showed that the greater the number of DLIs
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FIGURE 2 | Overall survival according to DLI indication.
FIGURE 3 | Overall survival according to donor.
administered, the greater the OS improvement. In our study,
about 60% of patients received a DLI schedule including more
than one DLI at escalating doses, with a median interval of
about 1 month between two subsequent infusions. A multiple
DLI schedule was administered in a higher percentage of patients
compared to previous registry studies, in which 49–61% of
patients received one single dose. The more favorable outcome
observed in our study for DLIs administered at least 2 years
after HCT could reflect the greater clinical benefit of DLIs in
late relapses in comparison with early recurrences after HCT,
as already reported (14). Multivariate analysis showed no better
outcome for patients who received chemotherapy or targeted
treatments in association with DLI. These treatments were
combined in 57% of patients at the time of first DLI and in a
much lower percentage of patients at the following infusions.
Although chemotherapy before DLI may theoretically induce
leukemia debulking and improve DLI response, no advantage
FIGURE 4 | Overall survival according to number of allogeneic transplants.
of chemotherapy plus DLI over DLI alone was observed in the
AML relapse (18) or pre-emptive settings (19). More promising
results were shown by hypomethylating agents: a few cycles
of azacitidine or decitabine before DLI in relapsed patients
with myeloid neoplasms could activate immune response and
promoted some long-term responses, even if the latter were
observed in small samples of patients and need confirmation in
larger prospective studies (20–23).
In our study, older age of recipients and haploidentical
donors were identified as adverse prognostic factors. Although
pediatric patients were included in the study, they represented
only 5% of the patients, therefore the worse outcome should
be probably referred to the elderly adult patients. Moreover, a
significantly shorter OS was reported by DLI from mismatched
related donors, who included almost exclusively haploidentical
donors. The inferior outcome seems to be caused by both lower
efficacy in leukemia relapses and more toxicity, in term of acute
GVHD, but these results should be interpreted with caution,
because of the small number of DLIs from haploidentical donors
and the heterogeneity of the GVHD prophylaxis platforms used
in our study. Moreover, median dose of the first DLI was 1
log lower after haploidentical transplants in comparison with
matched related and unrelated transplants and sequential doses
were administered less often after haploidentical than after other
HCTs: therefore, inferior doses could have impaired efficacy.
Large prospective studies comparing DLIs from haploidentical
and conventional donors are still lacking, particularly in the
setting of the leukemia relapse. In the context of a prophylactic
or pre-emptive strategy, a few small studies comparing T-
repleted haploidentical or HLA-identical DLIs in refractory or
very high-risk AML observed higher rates of acute GVHD
and NRM (24, 25), while a large recent prospective study
including 189 AL patients in first complete remission reported
a prolonged graft and relapse-free survival after haploidentical
HCT with an homogeneous ATG-based prophylaxis followed
by DLI in comparison with HCT from matched related donors
(26). Clinical trials are needed to establish the optimal timing
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and cell dose in both therapeutic and prophylactic settings after
haploidentical HCT and the relationship with GVHD and disease
response (27).
Although the GVL effect has been reported to be lower in
ALL than in myeloproliferative diseases (8, 16), in our study,
ALL patients had a long-term outcome comparable to that of
AML patients. Indeed, at present, other options such bispecific
antibodies or chimeric antigen receptor-T cells seem to be
more appealing than DLIs for the prevention and treatment of
ALL relapse.
DLI administration was followed by a second HCT in 46
patients. It could be hypothesized that the second transplant was
performed in patients not achieving a durable complete response
after DLI. Therefore, in these patients, DLI represented a “bridge
to” a second salvage HCT, allowing them to achieve a slight,
but not statistically significant, OS prolongation compared to
patients who received DLI alone.
We acknowledge that this study has some limitations. One is
the heterogeneity of recipient and donor features of the HCTs
included in the study, with 34 participating centers, the majority
of which provided data for <10 patients. Another limitation is
that only some of the Italian centers agreed to the second phase of
the study. Therefore, evaluation of toxicity and clinical response
to DLIs was based on a smaller patient population.
However, this survey presents the current “state of the art”
of DLI strategy in AL in Italy and allows us to make a few
practical and research considerations. From the organizational
point of view, the GITMO network may promote a policy of
DLI administration as pre-emptive treatment either allowing all
centers to detect MRD in AL patients in centralized laboratories
or accelerating authorization for leukaphereses from volunteer
donors. Moreover, this survey could be the basis for further
studies, either retrospective, including more homogeneous
populations, or prospective, aiming to address unresolved items,
such as DLI from haploidentical donors and DLI schedules
according to different indications and different donors.
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APPENDIX 1: PARTICIPANT CENTERS AND
PRINCIPAL INVESTIGATORS
CIC 141, Brescia: M. Malagola
CIC 163, Piacenza: D. Vallisa
CIC 231, Torino: L. Giaccone
CIC 232, Roma, “La Sapienza” University Hospital: A.P. Iori
CIC 240, Bologna: F. Bonifazi
CIC 245, Parma: L. Prezioso
CIC 248, Pescara: P. Olioso
CIC 265, Milano Ospedale Maggiore: F. Onida, G. Saporiti
CIC 286, Pavia: P. Bernasconi
CIC 299, Bolzano: I. Cavattoni
CIC 304, Firenze: A Gozzini
CIC 305, Candiolo: M Aglietta
CIC 307, Roma Università Cattolica SC:P.Chiusolo
CIC 331, Milano Istituto Europeo Oncologico: G. Martinelli
CIC 332, Taranto: G. Pisapia
CIC 354, Milano, Humanitas Cancer Center: L.Castagna
CIC 526, San Giovanni Rotondo (FG): A.M. Carella
CIC 544, Monza: P. Pioltelli
CIC 557, Pavia Clinica Pediatrica: M. Zecca
CIC 587, Reggio Calabria: T. Moscato
CIC 606, Cuneo: R. Sorasio, N. Mordini
CIC 623, Verona: A. Vassanelli
CIC 649, Bari: G. Specchia
CIC 658, Bergamo: A. Rambaldi, C. Micò
CIC 693, Palermo: M. Musso
CIC 705, Udine: F. Patriarca
CIC 756, Roma Tor Vergata: W. Arcese
CIC 788, Ancona: I. Scortechini
CIC 789, Napoli “Cardarelli”: A. Picardi
CIC 796, Roma “Bambin Gesù”: F. Locatelli
CIC 797, Vicenza: C. Borghero
CIC 811, Cagliari: E. Piras
CIC 813, Milano “San Raffaele”: F. Ciceri
CIC 825, Alessandria: M. Pini.
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